# DEBBRAH (NCT04420598)

> DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04420598
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: MedSIR
- Conditions: Advanced Breast Cancer; HER2-positive Breast Cancer; Brain Metastases; Leptomeningeal Metastasis
- Interventions: Trastuzumab deruxtecan
- Enrollment: 41
- Primary outcome: 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1)
- Primary outcome: Objective Response Rate According RANO-BM (Cohorts 2, 3 and 4)
- Primary outcome: Overall Survival in Cohort 5

## Commentary we found

- Podcasts: 5
- YouTube: 4
- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=debbrah-nct04420598

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04420598", "email": "<work email>"}; the inbox owner confirms by the emailed link.